What Is Semaglutide? Ozempic, Wegovy, and Rybelsus

One Drug. Three Products. Everything You Need to Know.

You have almost certainly heard the name. Ozempic has become shorthand for a new era of weight-loss medicine. But Ozempic, Wegovy, and Rybelsus are not three different drugs. They are three different products built around a single molecule: semaglutide. 

Understanding the distinctions between them matters because each product has a different approved use, a different dose, and a different administration method. Here is what science actually says.

1. What Exactly Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist: a synthetic molecule that mimics a hormone your gut releases naturally after eating. 

This hormone, GLP-1, tells your brain you are full, slows how quickly food leaves your stomach, and prompts your pancreas to release insulin in response to rising blood sugar.

What makes semaglutide different from the natural hormone is durability. Natural GLP-1 breaks down within minutes. 

Semaglutide is engineered with a fatty acid chain that binds it to albumin, a blood protein, extending its active half-life to approximately one week. That single structural change is what makes a once-weekly injection possible.

Semaglutide was developed by Novo Nordisk and first approved by the U.S. Food and Drug Administration in December 2017. As of 2025, it holds FDA approvals across three brand names, each with distinct indications, doses, and delivery formats.

The NCBI StatPearls review on semaglutide confirms that all three brands (Ozempic, Wegovy, and Rybelsus) are the same active compound with the same mechanism of action, differentiated only by dose, route of administration, and regulatory indication.

2. Three Products, One Molecule: What Sets Them Apart?

This is where most people get confused. The table below shows the key differences at a glance.

Ozempic: The Diabetes Injection

Ozempic is a weekly subcutaneous injection approved for adults with type 2 diabetes to improve blood glucose control. 

It also carries FDA approval to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes who have established heart disease.

In January 2025, the FDA further approved Ozempic to slow kidney disease progression in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial, which showed a 24% reduction in the composite risk of kidney failure, significant loss of kidney function, or death from kidney-related or cardiovascular causes.

Ozempic is not FDA-approved for weight loss. When doctors prescribe it for weight management, that is an off-label use.

Wegovy: The Weight Management Injection

Wegovy is the higher-dose weekly injection of semaglutide, approved specifically for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.

In 2023, Wegovy became the first weight-loss medication approved by the FDA to also reduce the risk of heart attack, stroke, and cardiovascular death, following results from the SELECT trial. 

In 2025, the FDA expanded its indication to include treatment of non-cirrhotic metabolic-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.

The maintenance dose for Wegovy is 2.4 mg once weekly, which is meaningfully higher than the diabetes doses used in Ozempic. This dose difference is a key reason Wegovy produces greater weight loss than Ozempic when the latter is used off-label for weight management.

Rybelsus: The Daily Oral Tablet

Rybelsus is the only oral semaglutide currently available in India and globally for type 2 diabetes management. 

It works by using a proprietary absorption enhancer (SNAC technology) that protects the peptide from breaking down in the stomach long enough for it to be absorbed.

The administration requirement is strict: one tablet taken on an empty stomach every morning, with no more than half a glass of plain water, at least 30 minutes before eating, drinking anything else, or taking other oral medications. 

Deviating from this protocol significantly reduces the amount of drug that reaches your bloodstream.

Rybelsus is not approved for weight loss in India. Its maximum dose of 14 mg daily is also below the doses used in weight-management research. Some physicians prescribe it off-label for this purpose, but the evidence base for weight loss is substantially stronger with Wegovy’s higher doses.

In October 2025, the FDA expanded Rybelsus’s label to include cardiovascular risk reduction in adults with type 2 diabetes who are at high risk for these events.

3. How Does Semaglutide Work in the Body?

Semaglutide acts on GLP-1 receptors distributed throughout the body. Its effects extend well beyond the gut.

In the Brain

GLP-1 receptors exist in the hypothalamus, the brain region that governs hunger and satiety. Semaglutide activates these receptors, suppressing appetite and reducing food cravings. 

Clinical observations suggest it may also reduce the reward value of highly palatable foods, which partly explains why people on semaglutide often report that food feels less compelling.

In the Pancreas

Semaglutide stimulates insulin secretion from beta cells in the pancreas, but only when blood glucose is elevated. 

This glucose-dependent mechanism is important: it means the drug does not cause dangerous drops in blood sugar (hypoglycaemia) on its own, unlike some older diabetes medications.

It also suppresses glucagon, the hormone that tells the liver to release stored glucose into the bloodstream. Lower glucagon means less unnecessary glucose production when you do not need it.

In the Stomach

Semaglutide slows gastric emptying: the rate at which your stomach pushes food into the small intestine. Slower gastric emptying means food stays in the stomach longer, extending the feeling of fullness after meals. This also blunts post-meal blood glucose spikes.

This delayed gastric emptying is also responsible for most of the gastrointestinal side effects. Food that lingers can cause nausea, and semaglutide constipation is one of the most persistent complaints, particularly in the early weeks of treatment.

Beyond Blood Sugar and Weight

Research published in Emerging Frontiers in GLP-1 Therapeutics (PMC, 2025) documents that GLP-1 receptors are found in the heart, kidneys, liver, and lungs. 

Semaglutide’s effects on these organs are being actively studied. Established benefits now include cardiovascular risk reduction, kidney protection, and emerging evidence for liver disease (MASH). 

Research into effects on inflammation, bone density, and metabolic function continues across 458 registered clinical trials as of late 2024.

4. What Do Clinical Trials Show About Weight Loss?

The weight-loss evidence for semaglutide is built on the STEP (Semaglutide Treatment Effect in People with Obesity) programme: a series of phase-3 randomised controlled trials that collectively enrolled tens of thousands of participants across multiple countries. 

All trials used semaglutide 2.4 mg once weekly (Wegovy dose) alongside dietary counselling and physical activity support.

Sources: STEP 1 trial (Wilding et al., NEJM 2021); STEP 2 trial (Davies et al., The Lancet 2021); STEP 5 trial (Garvey et al., Nature Medicine 2022); SELECT trial long-term weight analysis (Nature Medicine 2024).

A critical finding from the STEP 5 extension data: participants who stopped semaglutide at week 68 regained approximately two-thirds of their lost weight within one year. 

This tells us that semaglutide manages, rather than cures, obesity. Continuing treatment is necessary to maintain results.

The SELECT trial added another layer: in over 17,604 adults with pre-existing cardiovascular disease and overweight or obesity (but no diabetes), semaglutide 2.4 mg reduced major cardiovascular events by 20% compared to placebo over an average follow-up of 40 months. 

This was published in The New England Journal of Medicine in 2023 and formed the basis for Wegovy’s cardiovascular indication.

5. How Is Semaglutide Administered? Dosing and Titration

Semaglutide injections are started at a low dose and increased gradually over months. This titration process exists specifically to allow the body to adapt and to reduce gastrointestinal side effects.

Source: FDA Ozempic prescribing information; Drugs.com semaglutide dosage guide.

Injection Technique

Ozempic and Wegovy are injected subcutaneously (just under the skin) using a prefilled pen with a very fine needle (typically 4 mm, 32-gauge). Injections can be given in the abdomen, outer thigh, or upper arm.

• Rotate injection sites week to week to avoid skin irritation.
• The injection can be given at any time of day, with or without food.
• Keep pens refrigerated (2-8 degrees Celsius). Once in use, a pen may be stored at room temperature (below 30 degrees Celsius) for up to 56 days.
• Never share pens between patients, even if the needle is changed.

Rybelsus Administration

• Take one tablet daily, first thing in the morning.
• Use no more than half a glass of plain water (approximately 120 ml). No other liquids.
• Wait at least 30 minutes before eating, drinking anything except water, or taking other oral medications.
• Swallow tablets whole. Do not split, crush, or chew.

These restrictions exist because semaglutide is a peptide that stomach acid and food can break down rapidly. The absorption window is narrow, and any deviation substantially reduces how much reaches the bloodstream.

6. What Are the Side Effects and Who Should Not Use It?

Beyond the table above, two effects deserve special mention because they are commonly reported in real-world use but underrepresented in trial summaries: semaglutide hair loss (typically a temporary telogen effluvium tied to rapid weight loss) and semaglutide fatigue (often linked to reduced calorie intake and dehydration during titration).

Source: Mayo Clinic semaglutide side effects; MedlinePlus semaglutide injection; FDA Ozempic prescribing information.

Who Should Not Use Semaglutide?

Semaglutide carries a boxed warning (the FDA’s strongest safety alert) regarding the potential for medullary thyroid carcinoma. 

This was observed in rodent studies; whether it applies to humans is not confirmed. Nevertheless, semaglutide is contraindicated in people with:

• A personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• A prior serious hypersensitivity reaction to semaglutide or any of its components.
• Pregnancy (Novo Nordisk maintains a pregnancy exposure registry; discuss with your doctor immediately if you become pregnant while on semaglutide).

Use with caution if you have a history of pancreatitis, gallbladder disease, diabetic retinopathy, or kidney impairment. Talk with your doctor about all medications you take, as semaglutide’s effect on gastric emptying can alter the absorption of other oral drugs.

7. What Is the Semaglutide Landscape in India Right Now?

March 20, 2026 marked a significant shift for Indian patients: semaglutide’s key manufacturing patent (Patent No. 262697) expired in India, opening the market to generic competition. 

More than 40 Indian pharmaceutical companies began launching their versions within days, with Novo Nordisk’s branded Wegovy having entered India in June 2025.

Source: BusinessToday: India’s Semaglutide Generic Market; FiercePharma: Generic semaglutide launches in India.

India is the second-largest diabetes market globally, with approximately 90 million people living with the condition. 

The availability of affordable generic semaglutide represents a meaningful shift in access. Generic brands are available by prescription; semaglutide remains a prescription-only medication regardless of brand.

Rybelsus (oral semaglutide) remains under separate patent protection due to its SNAC absorption technology, meaning no generic oral semaglutide is expected in the near term.

Any decisions about switching between brands, starting treatment, or adjusting doses should be made in consultation with a qualified physician. CDSCO-approved products meet the same regulatory standards as Novo Nordisk’s branded versions, but formulations and delivery devices vary. Discuss your specific brand with your doctor before switching.

Frequently Asked Questions

Q1. What is semaglutide and what brand names does it come in?

Ans. Semaglutide is a GLP-1 receptor agonist, a medication that mimics a gut hormone released after eating to regulate appetite and blood sugar. It is approved under three brand names: Ozempic (weekly injection for type 2 diabetes and cardiovascular risk reduction), Wegovy (weekly injection for weight management), and Rybelsus (daily oral tablet for type 2 diabetes). All three are manufactured by Novo Nordisk and are available only by prescription.

Q2. Is semaglutide the same as Ozempic or Wegovy?

Ans. Yes, in terms of the active molecule: all three brands contain the exact same compound, semaglutide. The differences are in dose, route of administration, and approved indication. Wegovy is approved for weight loss at a higher maintenance dose (2.4 mg weekly) compared to Ozempic’s diabetes doses (up to 2 mg weekly). Using Ozempic for weight loss is an off-label use and, at typical diabetes doses, generally produces less weight loss than Wegovy at its approved weight-management dose.

Q3. How much weight can you expect to lose on semaglutide?

Ans. In the STEP 1 trial, adults with obesity who took semaglutide 2.4 mg weekly for 68 weeks lost an average of 14.9% of their body weight, versus 2.4% with placebo. Results vary based on starting weight, diet, physical activity, and individual response. Importantly, most of this weight is regained within a year if the medication is stopped, meaning long-term or indefinite use may be necessary to sustain outcomes. Always combine treatment with dietary guidance and physical activity.

Q4. Is semaglutide available in India, and do I need a prescription?

Ans. Yes, semaglutide is available in India. Novo Nordisk launched Wegovy in India in June 2025, and Ozempic has been available for diabetes management before that. Following patent expiry in March 2026, more than 40 Indian generic manufacturers including Sun Pharma, Dr. Reddy’s, Zydus, and Mankind have launched their versions. A prescription from a qualified physician is required regardless of brand. Do not purchase semaglutide without a prescription or from unverified online sources.

Q5. What are the most common side effects of semaglutide?

Ans. The most frequently reported side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and abdominal pain. These occur in more than 10% of users and are most pronounced during dose escalation. Most people find they ease once they reach their maintenance dose. Rare but serious risks include acute pancreatitis, gallbladder disease, and acute kidney injury. The medication carries a boxed warning regarding the theoretical risk of medullary thyroid carcinoma (confirmed in rodents, not confirmed in humans). Consult your doctor immediately if you experience severe abdominal pain or any signs of an allergic reaction.